Press Releases

Media Focus

Samsung Biologics plans expansion to US, Europe

Samsung Biologics plans expansion to US, Europe
 

South Korea based Samsung Biologics, a pharmaceutical Contract Manufacturing Organization (CMO), recorded high for the fiscal year 2019, reporting 30.9% growth in sales at 701.6 billion won, and 64.6% growth in operating profit at 91.7 billion won compared to the previous year. 

 

The strong performance was driven by increased operations at all three manufacturing plants.  

 

Since its launch in 2011, Samsung Biologics has been expanding its service offerings beyond CMO with state-of-the-art development, manufacturing, and laboratory testing services. 

 

The company has continued positive momentum and recently further reinforced its manufacturing capabilities in small scale manufacturing and aseptic filling.

 

Meanwhile, Samsung Biologics is exploring and planning on further investment options both at home in Songdo and globally. 

 

In addition to studying expanding manufacturing capacity in Korea, Samsung Biologics officially announced at a recent global conference its plans to open the company's first CDO R&D lab abroad in San Francisco this year to widen its sales footprint and improve client proximity.

 

Samsung Biologics is reviewing further geographical expansion plans in other regions in the US, Europe, etc. that will work to bring even greater synergy through collaboration with the manufacturing site in the Songdo headquarters.

 

All rights are reserved by the media that published this article. 

1-15372.jpg
 

South Korea based Samsung Biologics, a pharmaceutical Contract Manufacturing Organization (CMO), recorded high for the fiscal year 2019, reporting 30.9% growth in sales at 701.6 billion won, and 64.6% growth in operating profit at 91.7 billion won compared to the previous year. 

 

The strong performance was driven by increased operations at all three manufacturing plants.  

 

Since its launch in 2011, Samsung Biologics has been expanding its service offerings beyond CMO with state-of-the-art development, manufacturing, and laboratory testing services. 

 

The company has continued positive momentum and recently further reinforced its manufacturing capabilities in small scale manufacturing and aseptic filling.

 

Meanwhile, Samsung Biologics is exploring and planning on further investment options both at home in Songdo and globally. 

 

In addition to studying expanding manufacturing capacity in Korea, Samsung Biologics officially announced at a recent global conference its plans to open the company's first CDO R&D lab abroad in San Francisco this year to widen its sales footprint and improve client proximity.

 

Samsung Biologics is reviewing further geographical expansion plans in other regions in the US, Europe, etc. that will work to bring even greater synergy through collaboration with the manufacturing site in the Songdo headquarters.

 

All rights are reserved by the media that published this article. 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION